行情

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

7.77
-0.19
-2.39%
已收盘, 19:29 12/11 EST
开盘
7.83
昨收
7.96
最高
8.08
最低
7.03
成交量
64.22万
成交额
--
52周最高
8.55
52周最低
2.000
市值
2.19亿
市盈率(TTM)
-3.0355
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NLTX 新闻

  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.21小时前
  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.1天前
  • Neoleukin Therapeutics Announces Scientific Advisory Board
  • GlobeNewswire.6天前
  • 意大利总理支持欧洲稳定机制改革 遭反对党批评
  • 中国新闻网.12/03 07:11

更多

所属板块

生物技术和医学研究
-0.30%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

NLTX 简况

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
展开

Webull提供Neoleukin Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。